Business Wire

Celgene to Present New Data from Clinical Trials on Oral OTEZLA® (apremilast) at American Academy of Dermatology Congress


Celgene Corporation (NASDAQ:CELG) today announced that findings from ongoing clinical trials of OTEZLA® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), conducted in patients with moderate or moderate to severe plaque psoriasis, and in adult patients (18 years or older) with active psoriatic arthritis, will be presented at the 75th Annual Meeting of the American Academy of Dermatology (AAD) in Orlando, Florida. Ten abstracts will be presented at the meeting.

Among the data that will be presented is an analysis of the phase 4 UNVEIL trial, which evaluates the clinical efficacy and safety of oral OTEZLA 30 mg twice daily compared with placebo at week 16 in patients with moderate plaque psoriasis [defined as a body surface area (BSA) involvement of 5-10 percent and a static Physician’s Global Assessment (sPGA) of 3] who were naïve to systemic and biologic therapy. At baseline, more than 80 percent of patients enrolled in the trial had previously received topical therapy.

"We are excited to present new clinical research to the scientific community at AAD showing the efficacy and safety of OTEZLA in a variety of studies in patients with plaque psoriasis, including longer-term data," said Scott Smith, President, Celgene Inflammation & Immunology. “Furthermore, we are eager to share the results from UNVEIL, which is the first trial to evaluate a systemic therapy in patients with moderate plaque psoriasis who have not previously been treated with a systemic therapy, including biologics.”

The following abstracts will be presented at American Academy of Dermatology as an exchange of scientific and clinical information (all times, EST):

Abstracts at a Glance
Abstract 4892; Sunday, March 5, 2017, 8:55 – 9:00 AM
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase 4 Study); Bruce Strober

Abstract 5432; Sunday, March 5, 2017, 10:30 – 10:35 AM
Efficacy of Apremilast on Quality of Life Measures in Patients With Moderate Plaque Psoriasis (UNVEIL Phase 4 Study); Jerry Bagel

Abstract 4927; Sunday, March 5, 2017, 8:40 – 8:45 AM
Long-term Safety of Apremilast Treatment in Psoriasis and Psoriatic Arthritis Patients: Pooled Analysis for 156 Weeks and Beyond in the ESTEEM 1 and 2 and PALACE 1-3 Phase 3 Trials; Jeffrey Crowley

Abstract 5139; Sunday, March 5, 2017, 11:10 – 11:15 AM
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-term (104-Week) Improvement in Fatigue in Patients With Psoriatic Arthritis: Pooled Results From 3 Phase III, Randomized, Controlled Trials; Arthur Kavanaugh

Abstract 5390; Sunday, March 5, 2017, 3:45 – 3:50 PM
Low Serious Infection Rates in Patients with Psoriasis and Psoriatic Arthritis Treated With Apremilast for 156 Weeks and Beyond: Pooled Analysis of the Phase 3 ESTEEM 1 and 2 and PALACE 1-3 Trials; David Pariser

Abstract 5436; Sunday, March 5, 2017, 8:25 – 8:30 AM
Safety and Efficacy of Apremilast Through 104 Weeks in Patients With Moderate to Severe Psoriasis Who Continued on Apremilast or Switched From Etanercept Treatment in the LIBERATE Study; Kristian Reich

Abstract 5413; Sunday, March 5, 2017, 10:25 – 10:30 AM
Apremilast Reduces IL-17F, IL-17A, IL-22, and TNF-α Plasma Protein Levels in Patients With Moderate to Severe Plaque Psoriasis: Pharmacodynamic and Correlative Results From Phase 2/3 Studies; James G. Krueger

Abstract 5137; Sunday, March 5, 2017, 11:50 – 11:55 AM
First “Real-World” Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the LAPIS-PSO Study: An Interim Analysis; Kristian Reich

Abstract 5437; Sunday, March 5, 2017, 1:00 – 1:05 PM
Real-World Burden of Comorbidities in US Patients With Psoriasis; Kamal Shah

Abstract 5439; Sunday, March 5, 2017, 12:35 – 12:40 PM
Evaluation of the PGAxBSA Composite Tool in Patients With Moderate vs. Moderate to Severe Plaque Psoriasis; Kristina Callis Duffin

OTEZLA is not indicated for the treatment of plaque psoriasis patients with BSA involvement of less than 10 percent or sPGA less than 3.


UNVEIL is the first prospective, randomized, controlled study to evaluate the clinical efficacy and safety of OTEZLA in patients with moderate plaque psoriasis (defined as a BSA involvement of 5-10 percent and sPGA of 3 based on a 0 to 5 scale) who were naïve to systemic and biologic therapies. Patients (n=221) were randomized 2:1 to receive either OTEZLA 30 mg twice daily or placebo for 16 weeks, followed by an open-label extension phase in which placebo patients were switched to OTEZLA through week 52. All doses were titrated over the first week of treatment. At baseline, more than 80 percent of patients had previously received topical therapy. The primary endpoint was the mean percentage change from baseline in the product of Physician's Global Assessment (PGA) and BSA (%) at week 16.

About OTEZLA ®

OTEZLA® (apremilast) 30 mg tablets is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels which is thought to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which OTEZLA exerts its therapeutic action in patients with psoriasis or psoriatic arthritis is not well defined.


Otezla® (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for the treatment of adult patients with active psoriatic arthritis.



Otezla (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation.

Warnings and Precautions

Depression: Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur.

Psoriasis: Treatment with Otezla is associated with an increase in adverse reactions of depression. During clinical trials, 1.3% (12/920) of patients treated with Otezla reported depression compared to 0.4% (2/506) on placebo; 0.1% (1/1308) of Otezla patients discontinued treatment due to depression compared with none on placebo (0/506). Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide.

Psoriatic Arthritis: During clinical trials, 1.0% (10/998) of patients treated with Otezla reported depression or depressed mood compared to 0.8% (4/495) treated with placebo; 0.3% (4/1441) of patients treated with Otezla discontinued treatment due to depression or depressed mood compared with none in placebo treated patients (0/495). Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo treated patients (0/495). Suicidal ideation and behavior were observed in 0.2% (3/1441) of patients on Otezla, compared to none on placebo (0/495). Two patients who received placebo committed suicide compared to none on Otezla.

Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla.

Psoriasis: Body weight loss of 5-10% occurred in 12% (96/784) of patients treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo.

Psoriatic Arthritis: Body weight loss of 5-10% was reported in 10% of patients taking Otezla and in 3.3% of patients taking placebo. Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla.

Drug Interactions: Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended.

Adverse Reactions

Psoriasis: Adverse reactions reported in ≥5% of patients were (Otezla%, placebo%): diarrhea (17, 6), nausea (17, 7), upper respiratory tract infection (9, 6), tension headache (8, 4), and headache (6, 4).

Psoriatic Arthritis: Adverse reactions reported in ≥2% of patients taking Otezla, that occurred at a frequency at least 1% higher than that observed in patients taking placebo, for up to 16 weeks (after the initial 5-day titration), were (Otezla%, placebo%): diarrhea (7.7, 1.6); nausea (8.9, 3.1); headache (5.9, 2.2); upper respiratory tract infection (3.9, 1.8); vomiting (3.2, 0.4); nasopharyngitis (2.6, 1.6); upper abdominal pain (2.0, 0.2).

Use in Specific Populations

Pregnancy and Nursing Mothers: Otezla is Pregnancy Category C; it has not been studied in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether apremilast or its metabolites are present in human milk. Caution should be exercised when Otezla is administered to a nursing woman.

Renal Impairment: Otezla dosage should be reduced in patients with severe renal impairment (creatinine clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing Information.

Please click here for Full Prescribing Information.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information please visit Follow Celgene on Social Media: @CelgenePinterest, LinkedInFaceBook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Contact information

Celgene Corporation
Patrick E. Flanigan III, 908-673-9969
Corporate Vice President, Investor Relations
Catherine Cantone, 908-897-4256
Senior Director, Corporate Communications

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

European Parliament - E-Cig: a Potential Step Forward for European Health According to LIAF – Lega Italiana Anti Fumo19.3.2018 10:00Pressemelding

The following is a statement from LIAF – Lega Italiana Anti Fumo: Use of e-cigarettes in the world is growing continuously. However, Europe is falling behind. It is essential that Europe exploits the potential of this technology to reduce the impact of smoking on European Public Health. For this reason, the Italian Anti-Smoking League (Lega Italiana Anti Fumo - LIAF), hosted by MEP Giovanni La Via (former Chair of the ENVI Committee), is bringing experts and policymakers to the European Parliament to discuss the benefits of electronic cigarettes. The event takes place on 20 March 2018 at 12.30 p.m. and will allow experts to exchange views on the potential of e-cigarettes to help reshape European health. Though this is a very important public health issue, the discussion has been absent from the European agenda. With cigarettes killing more than half a million smokers a month globally and almost 6 million Europeans now using e-cigarettes to move away from smoking, providing scientific e

USP Capital: Ex- Samsung and Google Managers Teamed up to Launch a New Virtual Economy Through an AR/VR Assets Blockchain Combined with Games Based on Google Maps API19.3.2018 09:45Pressemelding

The interest in AR/VR Technologies seems to be on the rise with the recent announcement that Google will open their MAPS API to developers to create the future of AR gaming and build upon the success of Pokemon Go. This type of new technologies is expected to create a new type of virtual economy, with new types of goods and services created and traded by players. At the forefront of this advance is Mossland, an AR game with a blockchain core created by a team of Ex-Samsung and Google managers and AR experts, which raised more than 5 million in only 38 minutes in January. Advisors to the project also include Jason Han, the CEO of Kakao Blockchain and Jeffrey Lim, previous Head of Google Campus Seoul. Mossland combines the mechanics of Pokemon Go and Monopoly, allowing players buy and trade real-world virtual properties such as the Eiffel Tower or the Empire State Building. Transactions will be secure and transparent thanks to the use of the Moss Coin (MOC), a blockchain based cryptocurr

Sabio Raises the Game for Customer Experience With Bright UK Acquisition19.3.2018 09:15Pressemelding

Customer experience solutions specialist Sabio has announced that it has acquired Bright UK Limited, the customer service data and analysis experts. Bright offers bespoke consultancy and SaaS data solutions that deliver insights to contact centres, allowing them to operate more effectively. It does this through a unique combination of real time customer feedback analysis, comparative benchmarking and employee surveys. The acquisition follows Lyceum Capital’s strategic investment in Sabio, and is part of an ongoing acquisition plan to broaden the company’s solution portfolio. Adding Bright complements Sabio’s March 2017 acquisition of Rapport, the SaaS software and analysis services vendor, and significantly strengthens Sabio’s insight services portfolio providing an unrivalled holistic approach to analyse customer and employee satisfaction, offering clients both a technological and a professional serviced approach to improving the service experience. “Sabio is focused on supporting our

JustPremium Launches Rich Video Product Suite19.3.2018 08:00Pressemelding

Programmatic rich media and video ad marketplace, JustPremium, has today announced the launch of a new product suite, Rich Video. The new offering allows clients to build multiple rich video ad units with a single click using the advertisers existing assets. Using Rich Video allows advertisers to create an engaging advert, leading to higher engagement and interaction rates. Ultimately these formats help create a better user experience and a higher return on investment. JustPremium launches this product at a time when quality video inventory has never been more in demand, and brand-safe video inventory that advertisers require has never been in shorter supply. Rich Video allows publishers to build multiple creative ad units in minutes, enabling them to test different options and optimise their message to give the best performance. By utilising the assets that have already been created for Facebook, Adwords and YouTube, this process allows advertisers to supercharge their existing conten

GovSat-1 Satellite Goes Operational19.3.2018 07:40Pressemelding

GovSat-1 enters operational service today, to provide secure communications to governmental and institutional users. GovSat-1 is the first satellite of GovSat, a public private partnership between the Government of Luxembourg and the world-leading satellite operator SES. The satellite was launched into space on 31 January on board a flight-proven SpaceX Falcon 9 rocket from Cape Canaveral Air Force Station, and has since undergone extensive testing. This press release features multimedia. View the full release here: GovSat-1 launch. (Photo: SpaceX) The multi-mission satellite is operated by GovSat from the Secure Mission Operations Centre in Luxembourg. The highly flexible and resilient GovSat-1 payload uses dedicated frequencies in X-band and military Ka-band. It enables an array of applications such as connectivity for theatres of operation, interconnection of institutional or defence sites, border control, Intelligence, Surve

Digi Communications N.V.: Announcement on the Convocation Date for the Company’s GSM Approving the 2017 Annual Report19.3.2018 07:34Pressemelding

The Company would like to inform its investors and the market that the Board of Directors anticipates that on Wednesday, 21 March 2018, it will convene the general shareholders meeting (the “GSM”) called to approve, among others, the 2017 Annual Report. On the same date, the Company will make public, among others, its 2017 Annual Report and the auditor’s report. In accordance with the provisions of the articles of association of the Company, the GSM is scheduled to take place on 2 May 2018. Therefore, we would like to inform you with respect to the update to the Company’s Financial Reporting Calendar for 2018, which is available on Digi’s website. For details, please access the Digi’s website: (Investor Relations Section). About Digi Communications NV Digi is the parent holding company of RCS & RDS, a leading provider of pay TV and telecommunications services in Romania and Hungary. In addition, RCS & RDS provides mobile services as an MVNO to the large Roman